UK markets closed
  • FTSE 100

    7,204.55
    +14.25 (+0.20%)
     
  • FTSE 250

    22,931.66
    +14.61 (+0.06%)
     
  • AIM

    1,234.19
    -7.18 (-0.58%)
     
  • GBP/EUR

    1.1800
    -0.0061 (-0.51%)
     
  • GBP/USD

    1.3760
    -0.0036 (-0.26%)
     
  • BTC-GBP

    43,907.64
    -867.41 (-1.94%)
     
  • CMC Crypto 200

    1,453.34
    -49.70 (-3.31%)
     
  • S&P 500

    4,544.90
    -4.88 (-0.11%)
     
  • DOW

    35,677.02
    +73.92 (+0.21%)
     
  • CRUDE OIL

    83.98
    +1.48 (+1.79%)
     
  • GOLD FUTURES

    1,793.10
    +11.20 (+0.63%)
     
  • NIKKEI 225

    28,804.85
    +96.27 (+0.34%)
     
  • HANG SENG

    26,126.93
    +109.40 (+0.42%)
     
  • DAX

    15,542.98
    +70.38 (+0.45%)
     
  • CAC 40

    6,733.69
    +47.52 (+0.71%)
     

Global Intranasal Drug Delivery Market to Reach $71.3 Billion by 2026

·26-min read

Abstract: Global Intranasal Drug Delivery Market to Reach $71. 3 Billion by 2026 . As a direct result of technological advancements and increasing awareness among physicians and patients, a number of drug delivery options, including implantable, injectable, ocular, nasal, pulmonary, topical, transdermal, and transmucosal, are available to patients and care providers.

New York, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Intranasal Drug Delivery Industry" - https://www.reportlinker.com/p05436898/?utm_source=GNW
The mode of delivering drugs to the target area of the patient body plays a decisive role in the effectiveness of the therapy. Pulmonary and nasal are the most popular approaches for drug delivery, owing to the ease of administration, particularly for patients requiring long-term therapy, improvement in quality of life of patients, the improved efficacy and bioavailability of administered drugs, lower risk of drug overdose, and easier compliance with stringent pharmaceutical regulations.

Nasal drug delivery route is suitable for systematic drug delivery, needleless vaccination, and for drug candidates with low oral absorption or vulnerable to first-pass effect in the human body. Intranasal drug delivery is a method involving the administration of drugs through the nasal cavity to produce a systemic or local therapeutic activity, with the exceptional vascular structure of the human nose making it suitable for administering small molecule drugs and biologics, and highly effective for treating local infections, and acute and chronic allergies. A plethora of local anesthetics, antibiotics, antihistamines, bronchodilators, calcium, corticosteroids, decongestant sprays, pain relief drugs, snuffs, supplements, vasoconstrictors and other drugs are administered through the intranasal route for chronic and acute treatments. Intranasal drugs are primarily administered in the form of ointments, sprays, powders, gels, and drops for treating allergic infections, analgesics, osteoporosis, vaccinations, pain management, anxiety, depression, and sexual dysfunction, among others.

Amid the COVID-19 crisis, the global market for Intranasal Drug Delivery estimated at US$49.5 Billion in the year 2020, is projected to reach a revised size of US$71.3 Billion by 2026, growing at a CAGR of 6.2% over the analysis period. Liquid Delivery Devices, one of the segments analyzed in the report, is projected to grow at a 5.8% CAGR to reach US$31.3 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Powder Delivery Devices segment is readjusted to a revised 7% CAGR for the next 7-year period. This segment currently accounts for a 31.5% share of the global Intranasal Drug Delivery market.

The U.S. Market is Estimated at $21.9 Billion in 2021, While China is Forecast to Reach $5.7 Billion by 2026

The Intranasal Drug Delivery market in the U.S. is estimated at US$21.9 Billion in the year 2021. The country currently accounts for a 42.05% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$5.7 Billion in the year 2026 trailing a CAGR of 8.4% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.8% and 5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR while Rest of European market (as defined in the study) will reach US$6.1 Billion by the close of the analysis period.

North America represents the leading global market for intranasal drug delivery, driven by the growing prevalence of respiratory disorders, such as asthma and COPD; the high adoption of drug delivery technique in healthcare institutions; and the growing affinity of patients for affordable generic drugs. Technological developments are among the major factors driving the growth of the US drug delivery industry. The US drug delivery market has recorded significant developments in the past few years, and the search for new technologies represent a perennial effort aimed at achieving incremental benefits. In addition to scientific advancements, other factors and issues such as availability of financial support, changing scientific policies, therapeutic protocols, government regulations, and market forces have a bearing on the drug delivery market.

Europe represents the second largest market for intranasal drug delivery, trailed by the Asia-Pacific. The European market is expected to showcase fast growth fueled by the rising prevalence of chronic illnesses targeted for intranasal therapeutics, the growing markets for geriatric care, pediatric care, and home healthcare. Emerging countries in Asia, the Middle East and Latin America, are expected to spearhead the growth of the global intranasal drug delivery market by virtue of the large pool of target patients, relatively stronger GDP growth, improving public and private healthcare infrastructure, increasing healthcare spending, and increasing penetration of medical insurance. The Asia-Pacific, led by countries such as India and China, is expected to exhibit strong growth through the burgeoning population, rising per capita incomes, increasing patient awareness about the benefits of intranasal drugs, and increasing investment from drug companies.

Pressurized Metered Dose Inhalers Segment to Reach $12 Billion by 2026

In the global Pressurized Metered Dose Inhalers segment, USA, Canada, Japan, China and Europe will drive the 6.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$7 Billion in the year 2020 will reach a projected size of US$10.6 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$837.6 Million by the year 2026, while Latin America will expand at a 7.5% CAGR through the analysis period.
Select Competitors (Total 77 Featured)

  • Aegis Therapeutics LLC

  • AptarGroup, Inc.

  • AstraZeneca Plc

  • Becton Dickinson and Company

  • GlaxoSmithKline Plc

  • Johnson & Johnson

  • Marina Biotech, Inc.

  • MedImmune, Inc.

  • Merck & Co., Inc.

  • Nemera

  • Novartis AG

  • OptiNose US Inc.

  • Pfizer Inc.

  • Valeant Pharmaceuticals International, Inc.




Read the full report: https://www.reportlinker.com/p05436898/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession
2020: A Year of Disruption & Transformation
As the Race between the Virus & Vaccines Intensifies, Where is
the World Economy Headed in 2021?
EXHIBIT 1: World Economic Growth Projections (Real GDP, Annual
% Change) for 2020 through 2022
Promising Intranasal Vaccines to Nip COVID-19 Virus at Point of
Entry
Rapid Progress despite Roadblocks
Nasal Sprays for Protection against COVID-19 Infection
Intranasal Drug Delivery: A Prelude
Leading Indications and APIs Amenable to Nasal Drug Delivery
Regional Market Analysis
Why Nasal Application is Garnering Notable Attention for Drug
Delivery
Limitations of Intranasal Drug Delivery
Overview of the Traditional Drug Administration Routes,
Molecular Weight Capabilities, and Dosage Range
Drug Delivery Pathways Related to the Nasal Cavity
Systemic delivery and Local Delivery Routes
Differences between Systemic Delivery and Local Effects
Challenges Involved In Formulating Nasal Drugs
Intranasal Cavity: An Attractive Drug Delivery Route to Cross
the Blood Brain Barrier
Nose-to-Brain Drug Delivery: An Evolving Area of Interest
Factors Inhibiting Nose-to-Brain Transportation of Drugs
Bioavailability: An Important Facet of Intranasal Drug Delivery
Traditional Vs. Advanced Intranasal Drug Formulation Types
Type of Nasal Delivery Vehicles with Select Therapeutic Agents
and Area of Application
Select FDA-Approved Nasal Products Compound (Trade Name)
Indication Dosage Form Year
Recent Market Activity

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
Rise in Prevalence of COPD Drives Opportunities
EXHIBIT 2: Global Prevalence of COPD: Percentage of Men and
Women Affected by Age Group
Pharmaceutical and Medical Device Companies Vie to Develop New
Intranasal Therapeutics for Allergic Rhinitis Patients
EXHIBIT 3: Prevalence Percentage of COPD, Asthma, and Allergic
Rhinitis for Select Countries
The US - FDA Approved Intranasal Corticosteroids (INAC) and
Intranasal Antihistamines (INAH) for Treating Allergic
Rhinitis
The US - FDA Approved Nasal Spray Medication Types (excluding
INAC & INAH) for Allergic Rhinitis Treatment
Intranasal Corticosteroids: A Potential Treatment for
Debilitating Chronic Rhinosinusitis Disease
Select Intranasal Corticosteroid Brands for Adult and Pediatric
Usage
Manufacturers Focus on Improved Nasal Delivery Platforms
Controlled Release Technology is the Buzz Word
Research on Nanocarrier-Based Intranasal Drug Delivery Systems
Picks Up Pace
Potential Role in Treatment and Management of Coronavirus
Infection
Self-Administration of Drugs Brings Intranasal Drug Delivery
into the Spotlight
Nasal Drug Delivery Offers New Opportunities for Drug
Developers as Patent Cliffs Usher in Dusk of Blockbuster Era
EXHIBIT 4: Top Nasal Inhalers, Sprays, and Drops Brands in the
US (2019): Percentage Share Breakdown of Dollar Sales
Active Pharmaceutical Ingredients Used in Formulations for
Nasal Drug Delivery with Related Indications
Increasing R&D Unlocks New Therapeutic Areas for Nasal Drug
Delivery
Intranasal Therapeutics Delivery: A High Potential Method for
Treating CNS Diseases
Researchers Develop Nasal Spray Treatment for Parkinson?s Disease
Future Opportunities in CNS Space
Intranasal Delivery of Stem Cells: A Primary Strategy for
Treatment of CNS Disorders
Intranasal Delivery of Stem Cells: Limitations
EXHIBIT 5: Diagnosed Prevalence Cases of Parkinson?s Disease
Across Select Countries
Intranasal Delivery of Peptide-Based Pharmaceuticals
Select Protein, Peptide & Non-Peptide Drugs Available as Nasal
Spray Solutions in the Marketplace
Select List of Nasal Biologics Available in the Market
Benefits of Bi-Directional Nasal Drug Delivery
Rise in Interest in Preservative-free Nasal Spray Formulations
Burgeoning Geriatric Populace Spurs Growing Demand for
Intranasal Drug Therapies
EXHIBIT 6: Global Aging Population Statistics for the 65+ Age
Group in Million by Geographic Region for the Years 2019,
2025, 2035 and 2050
Appendix: List of Select Intranasal Drugs in Phase III Clinical
Trials
Select Intranasal Drugs for Pain Management in Phase III
Clinical Trials
Select Intranasal Drugs for Cancer in Phase III Clinical Trials
Select Intranasal Drugs for Diabetes in Phase III Clinical Trials
Select Intranasal Drugs for Nasal Polyps in Phase III Clinical
Trials
Select Intranasal Drugs for Depression in Phase III Clinical
Trials
Select Intranasal Drugs for Chronic Sinusitis in Phase III
Clinical Trials
Select Intranasal Drugs for Migraine in Phase III Clinical Trials
Select Intranasal Drugs for Allergic Rhinitis in Phase III
Clinical Trials
Select Intranasal Drugs for Diabetes Mellitus in Phase III
Clinical Trials
Select Intranasal Drugs for Covid-19 in Phase III Clinical Trials
Select Intranasal Drugs for Covid-19 in Phase III Clinical Trials

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Intranasal Drug
Delivery by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Intranasal Drug Delivery by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2016 through 2019 and % CAGR

Table 3: World 11-Year Perspective for Intranasal Drug Delivery
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2016, 2021 & 2027

Table 4: World Current & Future Analysis for Liquid Delivery
Devices by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Liquid Delivery Devices by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2016 through 2019 and % CAGR

Table 6: World 11-Year Perspective for Liquid Delivery Devices
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2021 & 2027

Table 7: World Current & Future Analysis for Powder Delivery
Devices by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Powder Delivery Devices by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2016 through 2019 and % CAGR

Table 9: World 11-Year Perspective for Powder Delivery Devices
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2021 & 2027

Table 10: World Current & Future Analysis for Pressurized
Metered Dose Inhalers by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Pressurized Metered Dose
Inhalers by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2016 through 2019 and % CAGR

Table 12: World 11-Year Perspective for Pressurized Metered
Dose Inhalers by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2016, 2021 & 2027

Table 13: World Current & Future Analysis for Other Product
Types by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 14: World Historic Review for Other Product Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2016 through 2019 and % CAGR

Table 15: World 11-Year Perspective for Other Product Types by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2021 & 2027

Table 16: World Current & Future Analysis for Respiratory
Disorders by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Respiratory Disorders by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2016 through 2019 and % CAGR

Table 18: World 11-Year Perspective for Respiratory Disorders
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2021 & 2027

Table 19: World Current & Future Analysis for Neurological
Disorders by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Neurological Disorders by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2016 through 2019 and % CAGR

Table 21: World 11-Year Perspective for Neurological Disorders
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2021 & 2027

Table 22: World Current & Future Analysis for Pain Management
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 23: World Historic Review for Pain Management by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2016 through 2019 and % CAGR

Table 24: World 11-Year Perspective for Pain Management by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2021 & 2027

Table 25: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2016 through 2019 and % CAGR

Table 27: World 11-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2016, 2021 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 28: USA Current & Future Analysis for Intranasal Drug
Delivery by Product Type - Liquid Delivery Devices, Powder
Delivery Devices, Pressurized Metered Dose Inhalers and Other
Product Types - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 29: USA Historic Review for Intranasal Drug Delivery by
Product Type - Liquid Delivery Devices, Powder Delivery
Devices, Pressurized Metered Dose Inhalers and Other Product
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2016 through 2019 and % CAGR

Table 30: USA 11-Year Perspective for Intranasal Drug Delivery
by Product Type - Percentage Breakdown of Value Sales for
Liquid Delivery Devices, Powder Delivery Devices, Pressurized
Metered Dose Inhalers and Other Product Types for the Years
2016, 2021 & 2027

Table 31: USA Current & Future Analysis for Intranasal Drug
Delivery by Application - Respiratory Disorders, Neurological
Disorders, Pain Management and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 32: USA Historic Review for Intranasal Drug Delivery by
Application - Respiratory Disorders, Neurological Disorders,
Pain Management and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2016 through
2019 and % CAGR

Table 33: USA 11-Year Perspective for Intranasal Drug Delivery
by Application - Percentage Breakdown of Value Sales for
Respiratory Disorders, Neurological Disorders, Pain Management
and Other Applications for the Years 2016, 2021 & 2027

CANADA
Table 34: Canada Current & Future Analysis for Intranasal Drug
Delivery by Product Type - Liquid Delivery Devices, Powder
Delivery Devices, Pressurized Metered Dose Inhalers and Other
Product Types - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 35: Canada Historic Review for Intranasal Drug Delivery
by Product Type - Liquid Delivery Devices, Powder Delivery
Devices, Pressurized Metered Dose Inhalers and Other Product
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2016 through 2019 and % CAGR

Table 36: Canada 11-Year Perspective for Intranasal Drug
Delivery by Product Type - Percentage Breakdown of Value Sales
for Liquid Delivery Devices, Powder Delivery Devices,
Pressurized Metered Dose Inhalers and Other Product Types for
the Years 2016, 2021 & 2027

Table 37: Canada Current & Future Analysis for Intranasal Drug
Delivery by Application - Respiratory Disorders, Neurological
Disorders, Pain Management and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 38: Canada Historic Review for Intranasal Drug Delivery
by Application - Respiratory Disorders, Neurological Disorders,
Pain Management and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2016 through
2019 and % CAGR

Table 39: Canada 11-Year Perspective for Intranasal Drug
Delivery by Application - Percentage Breakdown of Value Sales
for Respiratory Disorders, Neurological Disorders, Pain
Management and Other Applications for the Years 2016, 2021 &
2027

JAPAN
Table 40: Japan Current & Future Analysis for Intranasal Drug
Delivery by Product Type - Liquid Delivery Devices, Powder
Delivery Devices, Pressurized Metered Dose Inhalers and Other
Product Types - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 41: Japan Historic Review for Intranasal Drug Delivery by
Product Type - Liquid Delivery Devices, Powder Delivery
Devices, Pressurized Metered Dose Inhalers and Other Product
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2016 through 2019 and % CAGR

Table 42: Japan 11-Year Perspective for Intranasal Drug
Delivery by Product Type - Percentage Breakdown of Value Sales
for Liquid Delivery Devices, Powder Delivery Devices,
Pressurized Metered Dose Inhalers and Other Product Types for
the Years 2016, 2021 & 2027

Table 43: Japan Current & Future Analysis for Intranasal Drug
Delivery by Application - Respiratory Disorders, Neurological
Disorders, Pain Management and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 44: Japan Historic Review for Intranasal Drug Delivery by
Application - Respiratory Disorders, Neurological Disorders,
Pain Management and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2016 through
2019 and % CAGR

Table 45: Japan 11-Year Perspective for Intranasal Drug
Delivery by Application - Percentage Breakdown of Value Sales
for Respiratory Disorders, Neurological Disorders, Pain
Management and Other Applications for the Years 2016, 2021 &
2027

CHINA
Table 46: China Current & Future Analysis for Intranasal Drug
Delivery by Product Type - Liquid Delivery Devices, Powder
Delivery Devices, Pressurized Metered Dose Inhalers and Other
Product Types - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 47: China Historic Review for Intranasal Drug Delivery by
Product Type - Liquid Delivery Devices, Powder Delivery
Devices, Pressurized Metered Dose Inhalers and Other Product
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2016 through 2019 and % CAGR

Table 48: China 11-Year Perspective for Intranasal Drug
Delivery by Product Type - Percentage Breakdown of Value Sales
for Liquid Delivery Devices, Powder Delivery Devices,
Pressurized Metered Dose Inhalers and Other Product Types for
the Years 2016, 2021 & 2027

Table 49: China Current & Future Analysis for Intranasal Drug
Delivery by Application - Respiratory Disorders, Neurological
Disorders, Pain Management and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 50: China Historic Review for Intranasal Drug Delivery by
Application - Respiratory Disorders, Neurological Disorders,
Pain Management and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2016 through
2019 and % CAGR

Table 51: China 11-Year Perspective for Intranasal Drug
Delivery by Application - Percentage Breakdown of Value Sales
for Respiratory Disorders, Neurological Disorders, Pain
Management and Other Applications for the Years 2016, 2021 &
2027

EUROPE
Table 52: Europe Current & Future Analysis for Intranasal Drug
Delivery by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 53: Europe Historic Review for Intranasal Drug Delivery
by Geographic Region - France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2016 through 2019 and %
CAGR

Table 54: Europe 11-Year Perspective for Intranasal Drug
Delivery by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2016, 2021 & 2027

Table 55: Europe Current & Future Analysis for Intranasal Drug
Delivery by Product Type - Liquid Delivery Devices, Powder
Delivery Devices, Pressurized Metered Dose Inhalers and Other
Product Types - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 56: Europe Historic Review for Intranasal Drug Delivery
by Product Type - Liquid Delivery Devices, Powder Delivery
Devices, Pressurized Metered Dose Inhalers and Other Product
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2016 through 2019 and % CAGR

Table 57: Europe 11-Year Perspective for Intranasal Drug
Delivery by Product Type - Percentage Breakdown of Value Sales
for Liquid Delivery Devices, Powder Delivery Devices,
Pressurized Metered Dose Inhalers and Other Product Types for
the Years 2016, 2021 & 2027

Table 58: Europe Current & Future Analysis for Intranasal Drug
Delivery by Application - Respiratory Disorders, Neurological
Disorders, Pain Management and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 59: Europe Historic Review for Intranasal Drug Delivery
by Application - Respiratory Disorders, Neurological Disorders,
Pain Management and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2016 through
2019 and % CAGR

Table 60: Europe 11-Year Perspective for Intranasal Drug
Delivery by Application - Percentage Breakdown of Value Sales
for Respiratory Disorders, Neurological Disorders, Pain
Management and Other Applications for the Years 2016, 2021 &
2027

FRANCE
Table 61: France Current & Future Analysis for Intranasal Drug
Delivery by Product Type - Liquid Delivery Devices, Powder
Delivery Devices, Pressurized Metered Dose Inhalers and Other
Product Types - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 62: France Historic Review for Intranasal Drug Delivery
by Product Type - Liquid Delivery Devices, Powder Delivery
Devices, Pressurized Metered Dose Inhalers and Other Product
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2016 through 2019 and % CAGR

Table 63: France 11-Year Perspective for Intranasal Drug
Delivery by Product Type - Percentage Breakdown of Value Sales
for Liquid Delivery Devices, Powder Delivery Devices,
Pressurized Metered Dose Inhalers and Other Product Types for
the Years 2016, 2021 & 2027

Table 64: France Current & Future Analysis for Intranasal Drug
Delivery by Application - Respiratory Disorders, Neurological
Disorders, Pain Management and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 65: France Historic Review for Intranasal Drug Delivery
by Application - Respiratory Disorders, Neurological Disorders,
Pain Management and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2016 through
2019 and % CAGR

Table 66: France 11-Year Perspective for Intranasal Drug
Delivery by Application - Percentage Breakdown of Value Sales
for Respiratory Disorders, Neurological Disorders, Pain
Management and Other Applications for the Years 2016, 2021 &
2027

GERMANY
Table 67: Germany Current & Future Analysis for Intranasal Drug
Delivery by Product Type - Liquid Delivery Devices, Powder
Delivery Devices, Pressurized Metered Dose Inhalers and Other
Product Types - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 68: Germany Historic Review for Intranasal Drug Delivery
by Product Type - Liquid Delivery Devices, Powder Delivery
Devices, Pressurized Metered Dose Inhalers and Other Product
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2016 through 2019 and % CAGR

Table 69: Germany 11-Year Perspective for Intranasal Drug
Delivery by Product Type - Percentage Breakdown of Value Sales
for Liquid Delivery Devices, Powder Delivery Devices,
Pressurized Metered Dose Inhalers and Other Product Types for
the Years 2016, 2021 & 2027

Table 70: Germany Current & Future Analysis for Intranasal Drug
Delivery by Application - Respiratory Disorders, Neurological
Disorders, Pain Management and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 71: Germany Historic Review for Intranasal Drug Delivery
by Application - Respiratory Disorders, Neurological Disorders,
Pain Management and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2016 through
2019 and % CAGR

Table 72: Germany 11-Year Perspective for Intranasal Drug
Delivery by Application - Percentage Breakdown of Value Sales
for Respiratory Disorders, Neurological Disorders, Pain
Management and Other Applications for the Years 2016, 2021 &
2027

ITALY
Table 73: Italy Current & Future Analysis for Intranasal Drug
Delivery by Product Type - Liquid Delivery Devices, Powder
Delivery Devices, Pressurized Metered Dose Inhalers and Other
Product Types - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 74: Italy Historic Review for Intranasal Drug Delivery by
Product Type - Liquid Delivery Devices, Powder Delivery
Devices, Pressurized Metered Dose Inhalers and Other Product
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2016 through 2019 and % CAGR

Table 75: Italy 11-Year Perspective for Intranasal Drug
Delivery by Product Type - Percentage Breakdown of Value Sales
for Liquid Delivery Devices, Powder Delivery Devices,
Pressurized Metered Dose Inhalers and Other Product Types for
the Years 2016, 2021 & 2027

Table 76: Italy Current & Future Analysis for Intranasal Drug
Delivery by Application - Respiratory Disorders, Neurological
Disorders, Pain Management and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 77: Italy Historic Review for Intranasal Drug Delivery by
Application - Respiratory Disorders, Neurological Disorders,
Pain Management and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2016 through
2019 and % CAGR

Table 78: Italy 11-Year Perspective for Intranasal Drug
Delivery by Application - Percentage Breakdown of Value Sales
for Respiratory Disorders, Neurological Disorders, Pain
Management and Other Applications for the Years 2016, 2021 &
2027

UNITED KINGDOM
Table 79: UK Current & Future Analysis for Intranasal Drug
Delivery by Product Type - Liquid Delivery Devices, Powder
Delivery Devices, Pressurized Metered Dose Inhalers and Other
Product Types - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 80: UK Historic Review for Intranasal Drug Delivery by
Product Type - Liquid Delivery Devices, Powder Delivery
Devices, Pressurized Metered Dose Inhalers and Other Product
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2016 through 2019 and % CAGR

Table 81: UK 11-Year Perspective for Intranasal Drug Delivery
by Product Type - Percentage Breakdown of Value Sales for
Liquid Delivery Devices, Powder Delivery Devices, Pressurized
Metered Dose Inhalers and Other Product Types for the Years
2016, 2021 & 2027

Table 82: UK Current & Future Analysis for Intranasal Drug
Delivery by Application - Respiratory Disorders, Neurological
Disorders, Pain Management and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 83: UK Historic Review for Intranasal Drug Delivery by
Application - Respiratory Disorders, Neurological Disorders,
Pain Management and Other Applications Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2016 through
2019 and % CAGR

Table 84: UK 11-Year Perspective for Intranasal Drug Delivery
by Application - Percentage Breakdown of Value Sales for
Respiratory Disorders, Neurological Disorders, Pain Management
and Other Applications for the Years 2016, 2021 & 2027

SPAIN
Table 85: Spain Current & Future Analysis for Intranasal Drug
Delivery by Product Type - Liquid Delivery Devices, Powder
Delivery Devices, Pressurized Metered Dose Inhalers and Other
Product Types - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 86: Spain Historic Review for Intranasal Drug Delivery by
Product Type - Liquid Delivery Devices, Powder Delivery
Devices, Pressurized Metered Dose Inhalers and Other Product
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2016 through 2019 and % CAGR

Table 87: Spain 11-Year Perspective for Intranasal Drug
Delivery by Product Type - Percentage Breakdown of Value Sales
for Liquid Delivery Devices, Powder Delivery Devices,
Pressurized Metered Dose Inhalers and Other Product Types for
the Years 2016, 2021 & 2027

Table 88: Spain Current & Future Analysis for Intranasal Drug
Delivery by Application - Respiratory Disorders, Neurological
Disorders, Pain Management and Other Applications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR


Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05436898/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting